Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of JR-171 in Patients With Mucopolysaccharidosis Type I
jRCT2080225015Phase 2Completed
- Sponsor
- JCR Pharmaceuticals
- Start
- Jan 2020
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, single-arm trial of pabinafusp alfa in mucopolysaccharidosis type I, sponsored by JCR Pharmaceuticals. Started Jan 2020; status: completed.
02
Drugs
pabinafusp alfa
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on jRCT2080225015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225015.